Phases, active trials: Phase 1: 58, Phase 2: 121, Phase 3: 191, Other: 175
AstraZeneca operates one of the broadest oncology pipelines in the industry, with particular depth in lung cancer (Tagrisso/osimertinib and successors), ovarian and breast cancer (Lynparza/olaparib), and immuno-oncology (Imfinzi/durvalumab). The AstraZeneca/Daiichi-Sankyo collaboration on antibody-drug conjugates, including Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan, has reshaped the ADC landscape across HER2-expressing tumors. Outside oncology, AstraZeneca's CVRM franchise (Farxiga/dapagliflozin, Brilinta/ticagrelor) continues expanding indications into heart failure and chronic kidney disease.
- Oncology
- Lung cancer (EGFR/ALK/HER2)
- Ovarian cancer
- Breast cancer ADCs
- Cardiovascular / Metabolic
- Rare disease
- Tagrisso (osimertinib): EGFR-mutant NSCLC
- Lynparza (olaparib): BRCA-mutated cancers
- Imfinzi (durvalumab): PD-L1 checkpoint
- Enhertu (trastuzumab deruxtecan): HER2 ADC
- Dato-DXd (datopotamab deruxtecan): TROP2 ADC
- Calquence (acalabrutinib): B-cell malignancies
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of… NCT07390240 | Primary completion moved at least 3 years later Primary endpoints removed | Recruiting |
62 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in… NCT06008093 | Oct 23, 2026 · Estimated | Phase 2 |
30 more on the Completions page. See the calendar →
Monitor the AstraZeneca pipeline daily
Get a daily digest when AstraZeneca registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Breast Cancer | 22 |
| Asthma | 17 |
| Non-small Cell Lung Cancer | 16 |
| Systemic Lupus Erythematosus | 15 |
| Non-Small Cell Lung Cancer | 14 |
| Gastric Cancer | 13 |
| Hepatocellular Carcinoma | 13 |
| Ovarian Cancer | 12 |
AstraZeneca registers new combination trials for its ADC portfolio monthly. Monitoring their pipeline helps identify new competitive entries into HER2, TROP2, and EGFR-targeted spaces before they appear in analyst reports.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to AstraZeneca's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: AstraZeneca may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your AstraZeneca pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without… NCT06417814 | Active, Not Recruiting | Primary completion pushed from Sep 30, 2026 to Jan 11, 2027 | 2026-10-16 |
| A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With… NCT06764186 | Active, Not Recruiting | Study completion moved earlier from Dec 31, 2027 to Nov 30, 2027 | 2026-10-16 |
| A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese… NCT07686120 | Recruiting | Trial sites expanded: 0 → 51 locations | 2026-10-16 |
| Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC… NCT07711002 | Recruiting | Trial sites expanded: 2 → 210 locations | 2026-10-16 |
| Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in… NCT07109219 | Recruiting | Study completion pushed from Jul 3, 2028 to Jul 18, 2029 | 2026-10-16 |
Each trial page shows every change DataLookout has recorded for that trial.